WeChat as a Platform for Baduanjin Intervention in Patients With Stable Chronic Obstructive Pulmonary Disease in China: Retrospective Randomized Controlled Trial

Original Paper China Pulmonary Disease, Chronic Obstructive Surveys and Questionnaires Quality of Life Humans Retrospective Studies 3. Good health
DOI: 10.2196/23548 Publication Date: 2020-12-10T15:42:03Z
ABSTRACT
Pulmonary rehabilitation is a crucial part of the nonpharmacological treatment stable chronic obstructive pulmonary disease (COPD), but management remains problematic. WeChat could serve as useful tool in patient management. Baduanjin popular exercise China that usually applied rehabilitation, which has been confirmed to be effective improving lung function and life quality.This study aimed explore efficiency COPD patients.A total 200 patients from respiratory department Putuo Hospital participated project September 2018 October 2019, were randomly assigned control groups followed up using platform or telephone for 12 weeks. The frequency exercise, (percentage forced expiratory volume 1 second predicted, FEV1% predicted), assessment test (CAT) scores collected compared between two groups. number message exchanges satisfaction survey on used assess feasibility outside hospital.The significantly differed group (F=33.82, P<.001) across various time points (F=214.87, P<.001). After follow-up WeChat, there fewer not performing exercise. predicted value before after (Z=-3.686, (Z=-6.985, A significant difference was observed (Z=-3.679, CAT score (Z=-4.937, (Z=-5.246, completed exercises, function, active higher than those nonactive patients. All items scored with more 4 points. Among items, highest (mean 4.54, SD 0.77) continued management, by 4.46, 0.87). showed much enthusiasm compliance resulting better quality function. very satisfied because obvious curative effect home feeling.The provided feasible, effective, sustainable plan rehabilitation.Chinese Clinical Trial Registry ChiCTR1900028248; http://www.chictr.org.cn/showprojen.aspx?proj=46995.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (39)
CITATIONS (21)